Bull, Bear & Beyond by Edison Group

In this section, Wilkinson discusses how capital will be re-reinvested, with a balance struck between direct investments to capitalise on the current AI-driven technology shift and drive future vintages, secondary investments to take advantage of market pricing opportunities and the need to support their share price through buybacks. ****************************************************************...

In this interview, CEO Ben Wilkinson discusses Molten Ventures’ successful exits in 2024, which exceeded the £100m target, releasing £124m in capital through four main transactions:  Perkbox (1.3x return), Graphcore (slight loss but at book value), Endomag (nearly 4x return) and M-Files (7x return). ************************************************************************************** About ‘...

CQS Natural Resources Growth and Income is a differentiated closed-end investment company seeking opportunities across small- and mid-cap mining and resource stocks, which in our view deserves shareholder support during the upcoming general meeting. The cutoff time for proxy voting is 11am on 31 January, and you can view the company’s guide to voting here: https://cynprotectyourinvestment.com/ ***...

Edison’s investment companies team recently published an update on Edinburgh Worldwide Investment Trust – this company urgently needs its shareholders to vote. Saba Capital is attempting to replace the trust’s directors with Saba representatives, take over management of the assets and change the investment strategy. Edinburgh Worldwide’s general meeting is on 14 February; shareholders need to vote...

Actinogen Medical is an ASX-listed Australian biotech developing its lead asset, emestedastat (Xanamem), a specific and selective 11β-HSD1 inhibitor designed to prevent excess cortisol production in the brain and thereby reduce the progression of chronic neurodegenerative conditions such as Alzheimer’s disease (AD). Xanamem has also shown therapeutic activity in the treatment of major depressive d...

Get the lowdown from Edison’s Milosz Papst on this well-established investor and asset manager in the PE mid-market and a go-to partner for private company owners, especially families and founders, across Germany and neighbouring countries. ************************************************************************************** About ‘Bull, Bear & Beyond’ Bull, Bear & Beyond': features candi...

Get the lowdown from Edison’s Milosz Papst on this investment company which focuses on scalable private equity opportunities in Georgia. ************************************************************************************** About ‘Bull, Bear & Beyond’ Bull, Bear & Beyond': features candid conversations with senior executives and from our own team of experts from across industries, explorin...

In this interview, Greg Smith, CEO of IP Group, discusses the company’s recent achievements, including NAV stabilisation and successful exits that have strengthened the group’s position, enabling further investments and shareholder returns. He highlights the exits of Garrison, a cybersecurity firm sold to a private equity buyer for around £30m, and Featurespace, an AI fraud detection company being...

Get the lowdown from Edison’s Milosz Papst on this investment company whose objective is to achieve long-term capital appreciation by investing in a diversified portfolio of Vietnamese companies that have high growth potential and attractive valuations. ************************************************************************************** About ‘Bull, Bear & Beyond’ Bull, Bear & Beyond': f...

Mendus is an immuno-oncology company specialising in the field of allogeneic dendritic cell biology. It has two clinical-stage assets, vididencel and ilixadencel, both of which are off-the-shelf cell-based vaccines, designed to improve survival outcomes for cancer patients. Mendus is developing the lead programme, vididencel, as a maintenance therapy for acute myeloid leukaemia (AML). The company...

Baillie Gifford US Growth Trust (USA) is a London-listed investment trust which aims to produce long-term capital growth by investing predominantly in US companies. The trust invests in both publicly listed and privately owned companies. Its benchmark is the S&P 500 TR Index (in sterling). ************************************************************************************** About ‘Bull, Bear...

Patria Private Equity Trust's (PPET’s) investment objective is to achieve long-term total returns through holding a diversified portfolio of private equity funds and direct investments (co-investments and single-asset secondaries) alongside private equity managers, a majority of which will have a European focus. In this video, Alan Gauld, senior investment director of the Patria Global Private Mar...

With the gold price up more than 40% since early October 2023 and sitting close to all time highs, Wheaton Precious Metals’ President and CEO, Randy Smallwood, talks about the company’s unique business model and why it is the perfect investment to take advantage of higher prices in the future. ************************************************************************************** About ‘Bull, Bear...

In our final interview, Thomas provides an overview of Borussia Dortmund’s ESG initiatives. ************************************************************************************** About ‘Bull, Bear & Beyond’ Bull, Bear & Beyond': features candid conversations with senior executives and from our own team of experts from across industries, exploring strategy, innovation, and the opportunities...

In the fifth interview, we discuss Borussia Dortmund’s playing squad. The club has a strong reputation in identifying emerging talent and financial prudence in its investment in the squad. We focus on how the squad is developed and Borussia Dortmund is able to attract young talent, the key accounting issues with respect to the squad and the implications of the emergence of new leagues in the trans...

In the fourth interview, we focus on the company’s match operations revenue, namely the income from fans attending matches. Although it is Borussia Dortmund’s smallest revenue stream, at c 10% of the group total in FY24, attendance drives other revenues such as from merchandising and catering. We discuss the club’s enigmatic stadium, the fan-friendly philosophy on ticket prices and the investment...

In the third interview, Borussia Dortmund’s advertising revenue is the focus. Advertising, or sponsorship income, is the second most important revenue stream for the company, at 30% of the total in FY24. Thomas talks about the structure of the relationships with the various types of sponsors, how the company develops relationships with the sponsors and the growth drivers of sponsorship income. ***...

In the second interview, we discuss Borussia Dortmund’s TV marketing revenue. TV marketing is the company’s most important revenue stream, at c 40% of the group total, and over the long term has provided strong growth, a CAGR of c 15% in FY05–24. We focus on how the Bundesliga’s broadcasting rights compare with the other major European leagues, the opportunities for developing Bundesliga rights an...

In the first interview, we focus on the position of the company and the team in the football landscape. We discuss the attractive growth dynamics of football, why Borussia Dortmund should be thought of in a different way versus the perception that football clubs are not well run from a financial perspective, Borussia Dortmund’s positioning among the European football elite clubs and the company’s...

Oryzon Genomics is a Spanish biotechnology company focused on epigenetics. Its two lead assets, vafidemstat (central nervous system, CNS) and iadademstat (oncology), are in the clinical stages of development for various indications. Both are small molecule inhibitors of LSD1, a histone-modifying enzyme that forms part of complexes responsible for the regulation of genes implicated in CNS disorders...

Basilea Pharmaceutica, a Switzerland-based commercial-stage biotech company, specialises in developing innovative treatments for infectious diseases. In this video, CEO David Veitch highlights the urgent need for new therapies to combat severe bacterial and fungal infections. He also discusses the company's global commercial strategy and the compelling investment opportunity it presents. With a ma...

Halyk Bank is Kazakhstan’s leading financial services group, operating across a variety of segments, including retail, SME and corporate banking, insurance, leasing, brokerage and asset management. In this interview, Murat Koshenov, the company’s CFO and deputy CEO, discusses Halyk Bank’s position in the local banking sector and the company’s major growth drivers. He also comments on how the group...

Get the lowdown from Edison’s Milosz Papst on this investment company which seeks to achieve medium- to long-term capital appreciation through investment in assets in Vietnam, including listed equity, private equity and private credit. ************************************************************************************** About ‘Bull, Bear & Beyond’ Bull, Bear & Beyond': features candid con...

International Public Partnerships (INPP) is an infrastructure investment company that listed in 2006. It invests in a diversified portfolio of global public infrastructure assets and businesses, with a focus on availability-based or regulated revenues. INPP aims to provide investors with a consistent and predictable return from assets that meet societal and environmental needs, both now and in the...

Jalal Bagherli, chairman-elect of Nanoco Group, shares his experience in high-tech industries in discussing his forthcoming leadership role. With a history of turning around struggling companies, Jalal outlines the key steps Nanoco is taking, including a new strategy to maximise the value of its intellectual property (IP) and a process to explore potential sale options. He emphasises the importanc...